Local and Global News
BioAlberta, in partnership with Viresco Solutions, is conducting a survey of Alberta bioindustrial companies to gauge the size and features of the industry, and contribute towards an industry directory.
John Lewis, CEO of BioAlberta member Entos Pharmaceuticals and a lead research scientist at the Alberta Prostate Cancer Initiative, was featured in the Edmonton Journal discussing the potential of ultrasound as a prostate cancer biopsy tool.
Thursday, December 8, 2016
OncoQuest is developing an immunotherapeutic compound called Oregovomab to treat ovarian cancer. The drug is currently in a Phase 2B clinical trial at 13 centres in the U.S. and Italy.
The Canada-Alberta Job Grant (CAJG) is a funding program where employers and government share the cost of training new and existing employees to increase their knowledge and skills to meet the needs of Alberta’s changing economy.
Wednesday, November 30, 2016
Positive interim results reached from the Phase 2b clinical study of its lead product, oregovomab, in patients with advanced epithelial ovarian, adnexal or peritoneal carcinoma.
Thursday, November 24, 2016
SmileSonica proudly announces their orthodontic treatment "Aevo System" has received its medical device license from Health Canada.